Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 2
1991 1
1996 1
1998 2
2002 1
2003 1
2004 1
2005 6
2006 5
2007 4
2009 3
2010 3
2011 2
2012 1
2013 2
2014 3
2015 4
2016 5
2017 2
2018 1
2019 3
2020 5
2021 7
2022 10
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for Adam T. three
Search for Adam T. Threet instead (1 results)
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, Bollina P, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Powell P, Rosario DJ, Rowe E, Mason M, Catto JWF, Peters TJ, Oxley J, Williams NJ, Staffurth J, Neal DE; ProtecT Study Group. Hamdy FC, et al. N Engl J Med. 2023 Apr 27;388(17):1547-1558. doi: 10.1056/NEJMoa2214122. Epub 2023 Mar 11. N Engl J Med. 2023. PMID: 36912538 Clinical Trial.
Death from any cause occurred in 356 men (21.7%), with similar numbers in all three groups. Metastases developed in 51 men (9.4%) in the active-monitoring group, in 26 (4.7%) in the prostatectomy group, and in 27 (5.0%) in the radiotherapy group. ...
Death from any cause occurred in 356 men (21.7%), with similar numbers in all three groups. Metastases developed in 51 men (9.4%) in …
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. Hamdy FC, et al. N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14. N Engl J Med. 2016. PMID: 27626136 Free article. Clinical Trial.
In addition, no significant difference was seen among the groups in the number of deaths from any cause (169 deaths overall; P=0.87 for the comparison among the three groups). Metastases developed in more men in the active-monitoring group (33 men; 6.3 events per 1000 pers …
In addition, no significant difference was seen among the groups in the number of deaths from any cause (169 deaths overall; P=0.87 for the …
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE; ProtecT Study Group*. Donovan JL, et al. N Engl J Med. 2016 Oct 13;375(15):1425-1437. doi: 10.1056/NEJMoa1606221. Epub 2016 Sep 14. N Engl J Med. 2016. PMID: 27626365 Free PMC article. Clinical Trial.
RESULTS: The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prostatectomy had the greatest negative effect on sexual function and urinary continence, and although there was some recovery, these outcomes rem …
RESULTS: The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prosta …
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Lane JA, Donovan JL, Young GJ, Davis M, Walsh EI, Avery KNL, Blazeby JM, Mason MD, Martin RM, Peters TJ, Turner EL, Wade J, Bollina P, Catto JWF, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Neal DE, Hamdy FC, Metcalfe C; Prostate Testing for Cancer and Treatment (ProtecT) Study Group. Lane JA, et al. BJU Int. 2022 Sep;130(3):370-380. doi: 10.1111/bju.15739. Epub 2022 May 3. BJU Int. 2022. PMID: 35373443 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Men aged 50-69 years diagnosed with localised prostate cancer by prostate-specific antigen testing and biopsies at nine UK centres in the Prostate Testing for Cancer and Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. …
PATIENTS AND METHODS: Men aged 50-69 years diagnosed with localised prostate cancer by prostate-specific antigen testing and biopsies at nin …
Recent advances in techniques for fabrication and characterization of nanogap biosensors: A review.
Adam T, Dhahi TS, Gopinath SCB, Hashim U, Uda MNA. Adam T, et al. Biotechnol Appl Biochem. 2022 Aug;69(4):1395-1417. doi: 10.1002/bab.2212. Epub 2021 Aug 22. Biotechnol Appl Biochem. 2022. PMID: 34143905 Review.
Nanogap biosensors have fascinated researchers due to their excellent electrical properties. Nanogap biosensors comprise three arrays of electrodes that form nanometer-size gaps. The sensing gaps have become the major building blocks of several sensing applications, includ …
Nanogap biosensors have fascinated researchers due to their excellent electrical properties. Nanogap biosensors comprise three arrays …
Decision rules for personalized statin treatment prescriptions over multi-objectives.
Yew PY, Liang Y, Adam TJ, Wolfson J, Tonellato PJ, Chi CL. Yew PY, et al. Among authors: adam tj. Exp Biol Med (Maywood). 2023 Dec;248(24):2526-2537. doi: 10.1177/15353702231220660. Epub 2024 Jan 27. Exp Biol Med (Maywood). 2023. PMID: 38281069
The final decision rules were compact and efficient, resulting from a decision tree with only a maximum depth of 3 and 11 nodes. The DRST identified three factors that are easily obtainable at the point of care: age, low-density lipoprotein cholesterol (LDL-C) level, and a …
The final decision rules were compact and efficient, resulting from a decision tree with only a maximum depth of 3 and 11 nodes. The DRST id …
Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients.
Leistner R, Schroeter L, Adam T, Poddubnyy D, Stegemann M, Siegmund B, Maechler F, Geffers C, Schwab F, Gastmeier P, Treskatsch S, Angermair S, Schneider T. Leistner R, et al. Among authors: adam t. Crit Care. 2022 Jan 28;26(1):30. doi: 10.1186/s13054-022-03902-8. Crit Care. 2022. PMID: 35090528 Free PMC article.
CONCLUSION: In our study, dexamethasone therapy as recommended for COVID-19 was associated with a significant three times increase in the risk of CAPA. TRIAL REGISTRATION: Registration number DRKS00024578, Date of registration March 3rd, 2021....
CONCLUSION: In our study, dexamethasone therapy as recommended for COVID-19 was associated with a significant three times increase in …
Perceived stress as a predictor of eating behavior during the 3-year PREVIEW lifestyle intervention.
Jalo E, Konttinen H, Westerterp-Plantenga M, Adam T, Drummen M, Huttunen-Lenz M, Siig Vestentoft P, Martinez JA, Handjiev S, Macdonald I, Brand-Miller J, Poppitt S, Swindell N, Lam T, Navas-Carretero S, Handjieva-Darlenska T, Taylor M, Muirhead R, Silvestre MP, Raben A, Fogelholm M. Jalo E, et al. Among authors: adam t. Nutr Diabetes. 2022 Nov 5;12(1):47. doi: 10.1038/s41387-022-00224-0. Nutr Diabetes. 2022. PMID: 36335092 Free PMC article.
The first 6 months were considered an active behavior change stage and the remaining 2.5 years were considered a behavior maintenance stage. Eating behavior was measured using the Three Factor Eating Questionnaire and stress using the Perceived Stress Scale. ...
The first 6 months were considered an active behavior change stage and the remaining 2.5 years were considered a behavior maintenance stage. …
Using home monitoring technology to study the effects of traumatic brain injury in older multimorbid adults.
Parkinson ME, Doherty R, Curtis F, Soreq E, Lai HHL, Serban AI, Dani M, Fertleman M, Barnaghi P, Sharp DJ; UK Dementia Research Institute Care Research & Technology Research Group; Li LM. Parkinson ME, et al. Ann Clin Transl Neurol. 2023 Sep;10(9):1688-1694. doi: 10.1002/acn3.51849. Epub 2023 Aug 3. Ann Clin Transl Neurol. 2023. PMID: 37537851 Free PMC article.
The demographics of TBI are changing, and it is now a leading cause of hospitalisation in older adults. However, research in this population is minimal. We present three cases, showcasing the potential of in-home monitoring systems in understanding and managing early recov …
The demographics of TBI are changing, and it is now a leading cause of hospitalisation in older adults. However, research in this population …
Combined Targeted and Untargeted Profiling of HeLa Cells Deficient in Purine De Novo Synthesis.
Mádrová L, Součková O, Brumarová R, Dobešová D, Václavík J, Kouřil Š, de Sousa J, Friedecká J, Friedecký D, Barešová V, Zikánová M, Adam T. Mádrová L, et al. Among authors: adam t. Metabolites. 2022 Mar 13;12(3):241. doi: 10.3390/metabo12030241. Metabolites. 2022. PMID: 35323684 Free PMC article.
Three genetically determined enzyme defects of purine de novo synthesis (PDNS) have been identified so far in humans: adenylosuccinate lyase (ADSL) deficiency, 5-amino-4-imidazole carboxamide-ribosiduria (AICA-ribosiduria), and deficiency in bifunctional enzyme phosphoribo …
Three genetically determined enzyme defects of purine de novo synthesis (PDNS) have been identified so far in humans: adenylosuccinat …
73 results